Literature DB >> 3396488

The synergistic effect of cefotaxime and desacetylcefotaxime against clinical isolates of anaerobic bacteria.

H R Devlin1, L Boskovski.   

Abstract

The synergistic interaction of cefotaxime and desacetylcefotaxime against 187 clinically significant anaerobic organisms was investigated. Fusobacterium nucleatum, Actinomyces odontolyticus, propionibacteria, lactobacilli, peptostreptococci, Streptococcus intermedius and Veillonella were sensitive to cefotaxime. Both Eubacterium lentum and Streptococcus morbillorum were resistant. The susceptibility of the clostridia varied from 0.125 to greater than 256 mg/L; only 20% of species demonstrated synergy between cefotaxime and desacetylcefotaxime. The minimum inhibitory concentration (MIC) of cefotaxime against members of the genus Bacteroides ranged from 0.0625 to greater than 256 mg/L. The MIC50 of cefotaxime to Bacteroides fragilis and B. vulgatus was lowered from 6 and 4 mg/L, respectively, to 2 and 1 mg/L, respectively, when 4 mg/L desacetylcefotaxime was added to the medium. Full or partial synergy was demonstrated by 50.7% of the Bacteroides species tested. While cefotaxime and desacetylcefotaxime act synergistically against many members of the genus Bacteroides, the MIC of at least 10% of strains is not affected by this combination.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3396488     DOI: 10.2165/00003495-198800352-00011

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  12 in total

1.  Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites.

Authors:  G B ELION; S SINGER; G H HITCHINGS
Journal:  J Biol Chem       Date:  1954-06       Impact factor: 5.157

2.  An inocula replicating apparatus for routine testing of bacterial susceptibility to antibiotics.

Authors:  E STEERS; E L FOLTZ; B S GRAVES
Journal:  Antibiot Chemother (Northfield)       Date:  1959-05

3.  Preparing inoculum for susceptibility testing of anaerobes.

Authors:  J M Swenson; C Thornsberry
Journal:  J Clin Microbiol       Date:  1984-03       Impact factor: 5.948

4.  Human metabolism of cefotaxime.

Authors:  D S Reeves; L O White; H A Holt; D Bahari; M J Bywater; R P Bax
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

5.  Antimicrobial activity of HR810 against 419 strict anaerobic bacteria.

Authors:  R N Jones; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

6.  A method for testing for synergy with any number of agents.

Authors:  M C Berenbaum
Journal:  J Infect Dis       Date:  1978-02       Impact factor: 5.226

7.  The use of cefotaxime in a community hospital.

Authors:  S R Jones; W Levinson; R C Kimbrough; D Ditmer-Schutz
Journal:  Drug Intell Clin Pharm       Date:  1984-02

8.  The activity of cefotaxime and desacetylcefotaxime alone and in combination against anaerobes and staphylococci.

Authors:  R N Jones; A L Barry; R R Packer
Journal:  Diagn Microbiol Infect Dis       Date:  1984-06       Impact factor: 2.803

9.  In vitro synergy and potentiation between cefotaxime and desacetylcefotaxime against clinical isolates of Bacteroides.

Authors:  K E Aldridge; C V Sanders; R L Marier
Journal:  Diagn Microbiol Infect Dis       Date:  1984-06       Impact factor: 2.803

10.  The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal function.

Authors:  R M Ings; J P Fillastre; M Godin; A Leroy; G Humbert
Journal:  Rev Infect Dis       Date:  1982 Sep-Oct
View more
  1 in total

1.  Empyema thoracis and lung abscess due to Gemella morbillorum.

Authors:  C T da Costa; C Porter; K Parry; A Morris; A H Quoraishi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-01       Impact factor: 3.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.